mirvetuximab soravtansine (Elahere®)
Application Details
HSE100008
24051
mirvetuximab soravtansine
Elahere®
AbbVie
19/12/2024
14/11/2024
Application Status
NCPE Assessment Completed
25/06/2026
Full Health Technology Assessment Commissioned by HSE
26/02/2025
Rapid Review Completed
04/02/2025
Pricing and Reimbursement Application Complete
19/12/2024
Rapid Review Commissioned
17/12/2024